Boston Scientific’s ImageReady MRI device for the Vercise Gevia Deep Brain Stimulation (DBS) system has approved for use by the Food and Drug Administration (FDA) in a full-body environment.
The device is designed to treat patients with symptoms of Parkinson’s disease. Specifically, it aids in providing optimal symptom relief and controls unwanted side effects by emitting electrical signals to the brain.
Some of the side effects include shaking, muscle stiffness, and slowed movement. Therefore, the DBS is designed to lower the impact of such symptoms and boost the quality of life of those living with Parkinson’s disease.
Professor at Emory University’s department of neurosurgery, Dr Robert Gross, said: “When evaluating which DBS system is best for each of my patients, I always consider the immediate and long term needs my patient might have so that we can effectively address a patient's therapeutic needs even as their disease progresses.
“Customisable therapy, battery life, the size of the device, and access to MRI are factors patients should talk to their doctor about when they are considering deep brain stimulation.”
Studies have shown that those treated with the Vercise System had a 48 per cent improvement in their motor functions, in comparison to previous reports which only suggested 25 per cent.
The senior vice president and president, neuromodulation, at Boston Scientific, Maulik Nanavaty, added: "Boston Scientific continually strives to deliver new solutions that advance the field of neuromodulation and most importantly, result in better outcomes for our patients around the world.”